The tweet was deleted by the author.
But we saved everything 🙂.
Arcturus Therapeutics has released its financial results for the fourth quarter and fiscal year, providing investors with updated figures and insight into its mRNA therapeutic programs.
The company also disclosed progress across its clinical pipeline, highlighting developments in areas such as cystic fibrosis and rare diseases. Investors will closely watch how these advancements influence Arcturus Therapeutics outlook amid an increasingly competitive biotechnology sector.